Durysta — Finite-Lived Intangible Assets, Fair Value Disclosure
Products & Services · Finite-Lived Intangible Assets, Fair Value DisclosureAnalysis
StatementSegment
CategoryCapital Allocation
SignalHigher is better
VolatilityStable
First reportedQ3 2025
Last reportedQ3 2025
How to read this metric
An increase suggests rising market expectations for the product's future cash flows, while a decrease may indicate potential impairment or a reduction in the asset's remaining economic life.
Detailed definition
This metric represents the estimated fair value of the Durysta product line's finite-lived intangible assets as disclose...
Peer comparison
Comparable to 'Intangible Asset Fair Value' or 'Acquired Product Rights' reported by other pharmaceutical companies under purchase price allocation disclosures.
Metric ID:
abbv_segment_durysta_finite_lived_intangible_assets_fair_value_disclosureHistorical Data
1 periods
| Q3 '25 | |
|---|---|
| Value | $271.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's durysta — finite-lived intangible assets, fair value disclosure?
- AbbVie (ABBV) reported durysta — finite-lived intangible assets, fair value disclosure of $271.00M in Q3 2025.
- What does durysta — finite-lived intangible assets, fair value disclosure mean?
- The current estimated market value of the intellectual property and rights associated with the Durysta product line.